How BPC-157 Grows New Blood Vessels: The VEGFR2 Mechanism Explained
BPC-157 promotes blood vessel growth by increasing expression and activation of the VEGFR2 receptor and its downstream signaling pathway, explaining a key mechanism behind the peptide's healing effects.
Quick Facts
What This Study Found
BPC-157 promotes the growth of new blood vessels (angiogenesis) through a specific molecular mechanism: it increases the expression and internalization of VEGFR2, a key receptor for blood vessel growth, and activates the downstream VEGFR2-Akt-eNOS signaling pathway.
The study demonstrated this across multiple experimental models. In a chick embryo membrane assay, BPC-157 increased vessel density. In human endothelial cell cultures, it enhanced tube formation (a measure of blood vessel growth). Most notably, in rats with restricted blood flow to a hind limb (ischemia model), BPC-157 accelerated blood flow recovery and increased the number of blood vessels, with enhanced VEGFR2 expression confirmed by tissue analysis.
Importantly, BPC-157 upregulated the VEGFR2 receptor itself but not the VEGF-A ligand — meaning it works by making cells more responsive to existing growth signals rather than producing more growth factor. Blocking endocytosis with dynasore inhibited BPC-157's effects, confirming that receptor internalization is a required step in the mechanism.
Key Numbers
Increased vessel density in CAM assay · Enhanced tube formation in vitro · Accelerated blood flow recovery in rat ischemia model · VEGFR2 upregulation confirmed at mRNA and protein level · VEGFR2-Akt-eNOS pathway activation
How They Did This
Multi-model preclinical study combining: (1) chick chorioallantoic membrane (CAM) assay for in vivo angiogenesis, (2) human umbilical vein endothelial cell (HUVEC) tube formation assays in vitro, (3) rat hind limb ischemia model with laser Doppler blood flow scanning, and (4) molecular analysis of VEGFR2 expression, internalization, and downstream signaling. Dynasore (an endocytosis inhibitor) was used to confirm the mechanism.
Why This Research Matters
BPC-157 has been widely studied for its healing properties, but the molecular mechanism behind how it promotes tissue repair has been poorly understood. This study provides one of the clearest mechanistic explanations to date — showing that BPC-157 works by upregulating and activating the VEGFR2 pathway, which is the same pathway targeted by anti-cancer drugs (in reverse). Understanding this mechanism is crucial for evaluating both the therapeutic potential and safety implications of BPC-157.
The Bigger Picture
BPC-157 is one of the most discussed peptides in regenerative medicine, but skeptics have questioned its mechanisms. This study provides concrete molecular evidence for how BPC-157 promotes angiogenesis — through the same VEGFR2 pathway that is central to wound healing, tissue repair, and cancer biology. The finding that BPC-157 upregulates the receptor (not the growth factor itself) is a nuanced distinction that could inform future drug design and safety assessments.
What This Study Doesn't Tell Us
Animal and cell culture study only — no human data. The rat ischemia model, while informative, doesn't directly translate to human healing scenarios. Specific doses and concentrations used in each model aren't detailed in the abstract. The long-term effects and safety of VEGFR2 upregulation by BPC-157 are not addressed, which is relevant given that excessive angiogenesis can promote tumor growth.
Questions This Raises
- ?Does BPC-157's promotion of VEGFR2 and angiogenesis carry any risk of promoting tumor blood vessel growth in cancer contexts?
- ?Would this VEGFR2 mechanism translate to improved wound healing or tissue repair in human studies?
- ?How does the dose and route of BPC-157 administration affect the degree of VEGFR2 activation?
Trust & Context
- Key Stat:
- VEGFR2 pathway activated BPC-157 increased VEGFR2 expression at both mRNA and protein levels and activated the downstream Akt-eNOS signaling cascade that drives new blood vessel formation
- Evidence Grade:
- This is a well-designed preclinical study using multiple complementary models (in vivo, in vitro, mechanistic blocking experiments) published in a respected molecular medicine journal. However, it remains animal/cell data with no human evidence.
- Study Age:
- Published in 2017 in the Journal of Molecular Medicine. This remains one of the most cited mechanistic studies on BPC-157's angiogenic effects and is still frequently referenced in the field.
- Original Title:
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
- Published In:
- Journal of molecular medicine (Berlin, Germany), 95(3), 323-333 (2017)
- Authors:
- Hsieh, Ming-Jer(2), Liu, Hsien-Ta, Wang, Chao-Nin, Huang, Hsiu-Yun, Lin, Yuling, Ko, Yu-Shien, Wang, Jong-Shyan, Chang, Vincent Hung-Shu, Pang, Jong-Hwei S
- Database ID:
- RPEP-03322
Evidence Hierarchy
Frequently Asked Questions
How does BPC-157 help with healing at the molecular level?
This study shows BPC-157 increases the number and activity of VEGFR2 receptors on blood vessel cells. These receptors are the key switches that tell the body to grow new blood vessels. By making cells more responsive to vessel-growth signals and activating the Akt-eNOS pathway, BPC-157 promotes angiogenesis — the formation of new blood vessels that supply healing tissues with oxygen and nutrients.
Does BPC-157's blood vessel growth effect pose any cancer risk?
The study doesn't address this directly, but it's an important question. Tumors need new blood vessels to grow, and drugs that block VEGFR2 (like bevacizumab) are used in cancer treatment. Whether BPC-157's pro-angiogenic effect could theoretically promote tumor growth remains an open question that hasn't been studied in clinical settings.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03322APA
Hsieh, Ming-Jer; Liu, Hsien-Ta; Wang, Chao-Nin; Huang, Hsiu-Yun; Lin, Yuling; Ko, Yu-Shien; Wang, Jong-Shyan; Chang, Vincent Hung-Shu; Pang, Jong-Hwei S. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.. Journal of molecular medicine (Berlin, Germany), 95(3), 323-333. https://doi.org/10.1007/s00109-016-1488-y
MLA
Hsieh, Ming-Jer, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.." Journal of molecular medicine (Berlin, 2017. https://doi.org/10.1007/s00109-016-1488-y
RethinkPeptides
RethinkPeptides Research Database. "Therapeutic potential of pro-angiogenic BPC157 is associated..." RPEP-03322. Retrieved from https://rethinkpeptides.com/research/hsieh-2017-therapeutic-potential-of-proangiogenic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.